Physician profile
Julia Ellison
NPI 1518919406
$1,045.77
in general payments reported to CMS, 2019-2025
19 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2021: $92.13 · 2023: $96.27 · 2024: $340 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $177.92 | 2024-2025 | Ozempic, Wegovy |
| Astellas Pharma US INC | $118.49 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $103.05 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $92.13 | 2021 | |
| Pfizer INC. | $81.07 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $61.22 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.66 | 2024-2025 | |
| Amgen INC. | $54.45 | 2025 | Otezla, Repatha |
| Dynavax Technologies Corporation | $50.37 | 2023-2025 | Heplisav-B |
| Organon LLC | $45.80 | 2023-2024 | Nexplanon |
| Allergan, INC. | $42.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.89 | 2019-2024 | Farxiga |
| Aspira Women'S Health INC | $23.49 | 2024 | Ova1 |
| Sumitomo Pharma America, INC. | $21.14 | 2024 | Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.17 | 2024 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $16.60 | 2024 | Endosee |
| Kerecis Limited | $14.82 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2019 | |
| Glaxosmithkline, LLC. | $14.58 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.